Curtis T. Howard
Pfizer (United States)(US)
Publications by Year
Research Areas
HER2/EGFR in Cancer Research, PI3K/AKT/mTOR signaling in cancer, Click Chemistry and Applications, Metal complexes synthesis and properties, Synthesis and biological activity
Most-Cited Works
- → Tyrosine Kinase Inhibitors. 14. Structure−Activity Relationships for Methyl- amino-Substituted Derivatives of 4-[(3-Bromophenyl)amino]-6-(methylamino)- pyrido[3,4-d]pyrimidine (PD 158780), a Potent and Specific Inhibitor of the Tyrosine Kinase Activity of Receptors for the EGF Family of Growth Factors(1998)113 cited
- → Tyrosine Kinase Inhibitors. 6. Structure−Activity Relationships among N- and 3-Substituted 2,2‘-Diselenobis(1H-indoles) for Inhibition of Protein Tyrosine Kinases and Comparative in Vitro and in Vivo Studies against Selected Sulfur Congeners(1997)64 cited
- → Inhibition of the epidermal growth factor receptor tyrosine kinase by PD153035 in human A431 tumors in athymic nude mice(1995)59 cited
- Sequence and schedule-dependent synergy of trimetrexate in combination with 5-fluorouracil in vitro and in mice.(1989)
- Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2- methyl-1,4-butanediamine-N,N')platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo.(1994)
- PK/PD modeling of biomarker (p-ERK) response and tumor growth to PD 0325901 in a human tumor xenograft mouse model(2004)